Literature DB >> 23621602

Concurrent occurrence of primary intracranial Epstein-Barr virus-associated leiomyosarcoma and Hodgkin lymphoma in a young adult.

Hidehiro Takei1, Suzanne Powell, Andreana Rivera.   

Abstract

Although Epstein-Barr virus (EBV) infection has been known to be associated with a heterogeneous group of malignancies including Hodgkin lymphoma (HL), its association with smooth-muscle tumors (SMTs) has recently been described. Of these SMTs, a primary intracranial EBV-associated leiomyosarcoma (EBV-LMS) is extremely rare, and most of the reported cases were of immunocompromised and/or pediatric patients. A neurologically asymptomatic, previously healthy 27-year-old man was found to have a PET-positive brain lesion during a staging workup for his recently diagnosed HL. Subsequent MRI revealed a 2.6 × 4.0 × 3.3-cm inhomogeneously enhancing tumor with marked surrounding edema in the right anterior frontal lobe. He was serologically HIV negative. He underwent a right frontal lobectomy with gross-total resection of the tumor. Intraoperatively, the tumor had fairly discrete margins and appeared to arise from the anterior falx (that is, it was dural based). Microscopically, the tumor was composed of interlacing fascicles of spindle cells with brisk mitotic activity and multiple foci of necrosis. Immunohistochemically, the tumor cells were positive for caldesmon and smooth-muscle actin and negative for desmin, CD34, CD99, bcl-2, S100 protein, and GFAP. A Ki-67 labeling index was up to 30%. Epstein-Barr virus-encoded RNA in situ hybridization demonstrated strong diffuse positivity with more than 90% of tumor cells staining. Most of the Reed-Sternberg cells in HL were also labeled with Epstein-Barr virus-encoded RNA. This is the first case of a concurrent occurrence of rare intracranial EBV-LMS and HL in a seemingly "immunocompetent" adult patient (immunocompetence determined by routine laboratory data and clinical history). We should be aware of EBV-SMT as a differential diagnosis of dural-based spindle cell neoplasm in this setting given that patients with HL, even at presentation, exhibit a persistent defect in cellular immunity.

Entities:  

Mesh:

Year:  2013        PMID: 23621602     DOI: 10.3171/2013.3.JNS121707

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Surgical management and long-term outcomes of primary intracranial leiomyosarcoma: a case series and review of literature.

Authors:  Gui-Jun Zhang; Jian-Cong Weng; Xu-Lei Huo; Jun-Peng Ma; Bo Wang; Liang Wang; Huan Li; Da Li; Jun-Ting Zhang; Zhen Wu
Journal:  Neurosurg Rev       Date:  2020-10-24       Impact factor: 3.042

2.  Epstein Barr virus associated smooth muscle tumors in the central nervous system: a case report and systematic review of the literature.

Authors:  V M Willeke; M P Anderson; A Mahadevan; R Rojas; R Bhadelia; A J Thomas; E M Kasper
Journal:  J Neurooncol       Date:  2020-03-05       Impact factor: 4.130

3.  Pazopanib-mediated Long-term Disease Stabilization after Local Recurrence and Distant Metastasis of Primary Intracranial Leiomyosarcoma: A Case Report on the Efficacy of Pazopanib as a Salvage Therapy.

Authors:  Yasuhiro Kawabata; Tomokazu Aoki; Tetsurou Yamamoto; Hisateru Yasui; Satoru Sawai; Shunichi Fukuda; Satoru Kawarazaki; Tetsuya Tsukahara
Journal:  NMC Case Rep J       Date:  2017-12-07

4.  Primary intracranial leiomyosarcoma in an immunocompetent patient: Case report with emphasis on imaging features.

Authors:  Xiu-Li Li; Jing Ren; Run-Ning Niu; Xiao Jiang; Guo-Hui Xu; Peng Zhou; Zhu-Zhong Cheng
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

5.  Dyspnea due to an uncommon vascular tumor: leiomyosarcoma of the infrahepatic vena cava inferior.

Authors:  Samra Gafarli; Dorian Igna; Mathias Wagner; Adriana Nistor; Matthias Glanemann; Barbara Stange
Journal:  Surg Case Rep       Date:  2020-06-16

6.  Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review.

Authors:  Liyan Zhao; Yining Jiang; Yubo Wang; Yang Bai; Ying Sun; Yunqian Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.